×
Back to Agenda
Track 1 Session 5: Oncology Therapeutics: Minimizing Risks for Maximum Benefit
Session Chair(s)
Ritu Jaswal
Vice President - Pharmacovigilance Operations, Parexel, India
Track 1 Session 5: Oncology Therapeutics: Minimizing Risks For Maximum Benefit
Speaker(s)
Oncology Therapeutics At Novartis
Head Medical Safety Assessment and ESP Engagement , Novartis, India
Safety Profile/Risk Minimization Of Approved Chemotherapeutic Drugs
Senior Medical Safety Lead, Novartis, India
Risk Minimization For Developmental Oncology Drugs Including CAR-T And Radioligand Therapies
Global Program Safety Lead, Novartis, India
Learning From The Frontier: Risk Management In CAR-T Cell Immunotherapy For Haematological Malignancies
Head of Medical Affairs, Immuneel Therapeutics Private Limited, India
Have an account?